S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   266.09 (-1.56%)
AAPL   439.50 (-2.53%)
MSFT   204.05 (-2.02%)
FB   256.98 (-2.29%)
GOOGL   1,483.73 (-0.87%)
AMZN   3,085.67 (-1.98%)
NVDA   435.81 (-2.42%)
CGC   17.28 (-3.63%)
BABA   248.94 (+0.33%)
TSLA   1,376.17 (-2.99%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   77.17 (-6.16%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.11 (-1.08%)
GILD   68.10 (-0.60%)
NFLX   467.50 (-3.29%)
DIS   130.62 (+1.42%)
BAC   26.95 (+1.47%)
BA   180.70 (+0.72%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   266.09 (-1.56%)
AAPL   439.50 (-2.53%)
MSFT   204.05 (-2.02%)
FB   256.98 (-2.29%)
GOOGL   1,483.73 (-0.87%)
AMZN   3,085.67 (-1.98%)
NVDA   435.81 (-2.42%)
CGC   17.28 (-3.63%)
BABA   248.94 (+0.33%)
TSLA   1,376.17 (-2.99%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   77.17 (-6.16%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.11 (-1.08%)
GILD   68.10 (-0.60%)
NFLX   467.50 (-3.29%)
DIS   130.62 (+1.42%)
BAC   26.95 (+1.47%)
BA   180.70 (+0.72%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   266.09 (-1.56%)
AAPL   439.50 (-2.53%)
MSFT   204.05 (-2.02%)
FB   256.98 (-2.29%)
GOOGL   1,483.73 (-0.87%)
AMZN   3,085.67 (-1.98%)
NVDA   435.81 (-2.42%)
CGC   17.28 (-3.63%)
BABA   248.94 (+0.33%)
TSLA   1,376.17 (-2.99%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   77.17 (-6.16%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.11 (-1.08%)
GILD   68.10 (-0.60%)
NFLX   467.50 (-3.29%)
DIS   130.62 (+1.42%)
BAC   26.95 (+1.47%)
BA   180.70 (+0.72%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   266.09 (-1.56%)
AAPL   439.50 (-2.53%)
MSFT   204.05 (-2.02%)
FB   256.98 (-2.29%)
GOOGL   1,483.73 (-0.87%)
AMZN   3,085.67 (-1.98%)
NVDA   435.81 (-2.42%)
CGC   17.28 (-3.63%)
BABA   248.94 (+0.33%)
TSLA   1,376.17 (-2.99%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   77.17 (-6.16%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.11 (-1.08%)
GILD   68.10 (-0.60%)
NFLX   467.50 (-3.29%)
DIS   130.62 (+1.42%)
BAC   26.95 (+1.47%)
BA   180.70 (+0.72%)
Log in

NASDAQ:ILMNIllumina Stock Price, Forecast & News

$340.98
-12.37 (-3.50 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$340.00
Now: $340.98
$354.12
50-Day Range
$355.66
MA: $376.52
$400.74
52-Week Range
$196.78
Now: $340.98
$404.20
Volume48,585 shs
Average Volume977,415 shs
Market Capitalization$50.12 billion
P/E Ratio72.86
Dividend YieldN/A
Beta0.99
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a partnership with Lundbeck Foundation GeoGenetics Centre for exploring the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens; and an agreement with HTG Molecular Diagnostics, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More
Illumina logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.54 billion
Cash Flow$7.89 per share
Book Value$31.38 per share

Profitability

Net Income$1.00 billion

Miscellaneous

Employees7,700
Market Cap$50.12 billion
Next Earnings Date10/22/2020 (Estimated)
OptionableOptionable
$340.98
-12.37 (-3.50 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Illumina (NASDAQ:ILMN) Frequently Asked Questions

How has Illumina's stock price been impacted by Coronavirus?

Illumina's stock was trading at $246.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ILMN stock has increased by 38.6% and is now trading at $340.98.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Illumina?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Illumina
.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for Illumina
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) issued its earnings results on Thursday, August, 6th. The life sciences company reported $0.62 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.67 by $0.05. The life sciences company earned $633 million during the quarter, compared to analyst estimates of $682.07 million. Illumina had a return on equity of 19.13% and a net margin of 20.67%. The company's revenue for the quarter was down 24.5% on a year-over-year basis. During the same quarter last year, the business earned $1.35 EPS.
View Illumina's earnings history
.

What price target have analysts set for ILMN?

16 brokers have issued 12-month price targets for Illumina's shares. Their forecasts range from $290.00 to $390.00. On average, they expect Illumina's stock price to reach $341.31 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts' price targets for Illumina
.

Has Illumina been receiving favorable news coverage?

Press coverage about ILMN stock has been trending neutral recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Illumina earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned media coverage about the life sciences company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Illumina
.

Are investors shorting Illumina?

Illumina saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 3,220,000 shares, a decrease of 10.8% from the December 31st total of 3,610,000 shares. Based on an average daily volume of 957,800 shares, the days-to-cover ratio is currently 3.4 days. Currently, 2.2% of the shares of the stock are short sold.
View Illumina's Short Interest
.

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Visa (V), Walt Disney (DIS), salesforce.com (CRM), Paypal (PYPL), Micron Technology (MU) and Adobe (ADBE).

Who are Illumina's key executives?

Illumina's management team includes the following people:
  • Mr. Jay T. Flatley, Exec. Chairman (Age 66)
  • Mr. Francis A. deSouza, CEO, Pres & Director (Age 48)
  • Mr. Sam A. Samad, CFO & Sr. VP (Age 49)
  • Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)
  • Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 48)

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by a variety of retail and institutional investors. Top institutional investors include Copper Rock Capital Partners LLC (1.59%), Jennison Associates LLC (1.17%), Jackson Square Partners LLC (0.87%), Sumitomo Mitsui Trust Holdings Inc. (0.78%), Swiss National Bank (0.40%) and Principal Financial Group Inc. (0.30%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina
.

Which major investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Toronto Dominion Bank, Jackson Square Partners LLC, Kornitzer Capital Management Inc. KS, Jennison Associates LLC, Waverton Investment Management Ltd, PGGM Investments, and TCW Group Inc.. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina
.

Which major investors are buying Illumina stock?

ILMN stock was acquired by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, First Trust Advisors LP, Envestnet Asset Management Inc., Principal Financial Group Inc., Dock Street Asset Management Inc., CWM LLC, SG Americas Securities LLC, and Oregon Public Employees Retirement Fund.
View insider buying and selling activity for Illumina
.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $340.98.

How big of a company is Illumina?

Illumina has a market capitalization of $50.12 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.